Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;73(5):438-444.
doi: 10.1177/00033197211050446. Epub 2021 Oct 18.

Can Serum Endocan Levels be Used as an Early Prognostic Marker for Endothelial Dysfunction in COVID-19?

Duygu Guzel  1 , Emra Asfuroglu Kalkan  1 , Funda Eren  2 , Oguzhan Zengin  1 , Ozcan Erel  2 , Enes S Sahiner  1 , Osman Inan  1 , Ihsan Ates  1
Affiliations

Can Serum Endocan Levels be Used as an Early Prognostic Marker for Endothelial Dysfunction in COVID-19?

Duygu Guzel et al. Angiology. 2022 May.

Abstract

In this study, we aimed to investigate whether degree of pneumonia and COVID-19 prognosis are associated with serum endocan levels at the early stage, when vascular damage has started. Patients between the ages of 18-85 years who were hospitalized and followed up with a diagnosis of COVID-19 were included in the study. A total of 80 patients were divided into 2 groups as mild/moderate pneumonia and severe pneumonia. Serum endocan levels were measured on the 8th day from the onset of symptoms in all patients. Of the 80 patients included in the study, 56.3% were female and 43.8% were male. There was no significant relationship between serum endocan levels and degree of pneumonia (P = .220) and prognosis of the disease (P = .761). The correlation analysis indicated a weak positive correlation between serum endocan levels and lactate level in venous blood gas (r = .270; P = .037). During the 28-day follow-up, the mortality rate was 3.75%. It was determined that the serum endocan levels was not associated with the degree of pneumonia and was not an early prognostic marker for COVID-19.

Keywords: COVID-19; SARS-CoV-2; endocan; endothelial dysfunction.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Johnson M. Wuhan 2019 novel coronavirus - 2019-nCoV. Mater Methods 2020;10:1-5.
    1. Ambrosino P, Di Minno A, Maniscalco M, Di Minno MND. COVID-19 and venous thromboembolism: current insights and prophylactic strategies. Ann Med 2020;52(6):239-242. - PMC - PubMed
    1. Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. - PMC - PubMed
    1. Scuruchi M, D’Ascola A, Avenoso A, et al.Endocan, a novel inflammatory marker, is upregulated in human chondrocytes stimulated with IL-1 beta. Mol Cell Biochem. Published online2021;476(3):1-9. - PubMed
    1. Béchard D, Gentina T, Delehedde M, et al.Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 2001;276(51):48341-48349. - PubMed